caf®10b
Vaccineexperimental
Clinical trial activity
1 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 31, 2024 (NCT06050356)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Mycobacterium tuberculosisImmunity, active
Mycobacterium tuberculosis immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06050356 | Phase 1 | Jan 31, 2024 | Aurum Institute, Bill and Melinda Gates Foundation, Leiden University, South African Tuberculosis Vaccine Initiative (SATVI), Statens Serum Institut |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Aurum Institute | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Bill and Melinda Gates Foundation | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Leiden University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| South African Tuberculosis Vaccine Initiative (SATVI) | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Statens Serum Institut | Academic/Hospital | 1 | 1 | 1 | 2024 |
5 organizations
Page 1 / 1